亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Therapeutic Drug Monitoring in Psychiatry

作者
Andreas Conca,Pierre Baumann,Christoph Hiemke
出处
期刊:Pharmacopsychiatry [Thieme Medical Publishers (Germany)]
卷期号:44 (06): 193-194 被引量:1
标识
DOI:10.1055/s-0031-1286286
摘要

Therapeutic drug monitoring (TDM) is a tool for optimisation of pharmacotherapy. The absence of comprehensive guidelines regarding this technique in psychopharmacotherapy prompted a group of authors, the AGNP-TDM task force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP) to publish consensus guidelines for TDM in psychiatry in 2004 [ 1 ]. In the meantime, these guidelines experienced a successful disclosure (with almost 200 citations in the scientific literature) and acceptance. Many laboratories adopted the proposed reference ranges. However, new scientific realizations and increasing clinical knowledge lead to the categorical imperative to revise and update these guidelines. The new guidelines represent the core of this special issue of Pharmacopsychiatry. For TDM-guided pharmacotherapy, the whole clinical context, including patient specific variables and pharmacological properties of the drugs, must be taken into account to be of maximal benefit for treatment optimization. Literature based “therapeutic reference ranges” and “dose related reference ranges” were elaborated for 128 neuropsychiatric drugs after an extensive literature search and a broad and profound internal review process. A “laboratory alert level” for potentially toxic plasma levels was newly introduced guaranteeing the physician to be informed immediately in case of suspected intoxication. Supportive information such as cytochrome P450 substrate and inhibitor properties of drugs, “normal” ranges of ratios of concentrations drug metabolite to parent drug and recommendations for the interpretative services are given. This document aims at responding to the needs of psychiatrists and other physicians, clinical pharmacologists and TDM laboratories working in this field. During the IX th international congress of the interdisciplinary AGNP-TDM task force at Bolzano, Italy, in September 2010, the publication of the updated TDM consensus guidelines was definitely scheduled. It was also decided that other TDM relevant topics should be integrated into this special issue. Gründer and co-workers show that positron emission tomography (PET) of molecular drug targets in the brain (neurotransmitter receptors and transporters) allows to establish relationships between drug plasma levels and target concentrations in the brain, thereby providing guidance for TDM services of the most commonly used antidepressant and antipsychotic drugs. They give strong evidence for the assumption of rational pharmacotherapy that plasma concentrations are directly related to target occupancy by the respective drug in the brain. The contribution of Egberts and her colleagues deals with the conflicting issue of pharmacotherapy in children and adolescents. They describe how TDM studies in these age groups are necessary to identify age and specific therapeutic reference ranges of serum concentrations. They also outline the value of systematic collection of data on drug exposure, drug serum concentrations and on clinical characteristics such as outcome. This information helps to generate practice-based evidence for psychopharmacotherapy in a patient group that has many legal and ethical limitations to be studied prospectively in a broad way. The potential of TDM in pharmacovigilance and drug safety programs is described by Haen. In the so called AGATE ( A rbeits g emeinschaft A rzneimittel t herapie bei psychiatrischen E rkrankungen) net, more than 50 hospitals specialized in the treatment of psychiatric disorders in adults, adolescents and children (most of them in Germany) cooperate to promote rational drug therapy. The AGATE has become a net of pharmacocompetence in which pharmacovigilance is linked to pharmacoinformation to optimize therapeutic outcomes and prevent adverse drug effects (ADE). Despite existing evidence for the advantages of TDM and its positive impact on clinical reality, Conca and co-workers found a strong restriction of TDM to only few drugs and a weak knowledge base in their nationwide survey on TDM in Italian psychiatry. On the other hand, mental health workers in this country expressed a high interest for TDM. As a consequence, teaching about TDM should be developed systematically and laboratories should be encouraged to establish TDM services for psychotropic drugs. Finally, Stassen and colleagues deal with the prediction of response to psychopharmacological treatment in an excellent summary about their research beyond the rigorous pharmacokinetic and pharmacodynamic concepts. They explain the impact of the severity of illness, early onset of improvement, unwanted side-effects, and medical comorbidity as predictors of response. They corroborate the fact that the mechanisms by which antidepressants and antipsychotics ultimately exert their therapeutic effects are only marginally understood. Therefore, this contribution gives evidence that psychopharmacotherapy should not only consider TDM in accordance with the reported new guidelines, but also symptom rating to quantify the patient’s psychopathology. One of the highlights of the Bolzano meeting was the oral presentation by Hans Stassen. It was the special lecture in honour to the meritorious Prof. Dr. Bruno Müller-Oerlinghausen, who retired from the TDM group at this occasion, but who remains an honorary member of the task force. As former editor of Pharmacopsychiatry and head of the Drug Commission of the German Medical Association, he contributed to a large extent for the implementation of TDM as an officially accepted tool to guide psychopharmacotherapy. We wish to thank Prof. Dr. Bruno Müller-Oerlinghausen by dedication of this special issue. Last but not least, this issue is dedicated also to Prof. Dr. Marie Luise Rao and Dr. Hans-Joachim Kuss, who also retired from our TDM group after they had contributed substantially to the evolution of TDM in psychiatry during the last 3 decades. MLR’s input is documented by numerous publications on TDM for antipsychotic, antidepressant and mood stabilizing drugs, whereas HJK’s clinical studies, e. g., his report published 1984 in Lancet and entitled “Amitriptyline: looking through the therapeutic window” [ 2 ], and his achievements in analytical methodology considerably helped to implant TDM in psychiatry.· Andreas Conca, Pierre Baumann and Christoph Hiemke Bolzano, Italy, Lausanne, Switzerland, and Mainz, Germany

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
白丶魈白发布了新的文献求助10
1秒前
白丶魈白发布了新的文献求助10
1秒前
小太阳完成签到,获得积分10
1秒前
白丶魈白发布了新的文献求助10
2秒前
白丶魈白发布了新的文献求助10
2秒前
白丶魈白发布了新的文献求助10
2秒前
白丶魈白发布了新的文献求助10
2秒前
白丶魈白发布了新的文献求助10
2秒前
白丶魈白发布了新的文献求助10
2秒前
白丶魈白发布了新的文献求助10
2秒前
白丶魈白发布了新的文献求助10
3秒前
白丶魈白发布了新的文献求助10
3秒前
白丶魈白发布了新的文献求助10
3秒前
白丶魈白发布了新的文献求助10
3秒前
白丶魈白发布了新的文献求助10
3秒前
白丶魈白发布了新的文献求助10
3秒前
白丶魈白发布了新的文献求助10
3秒前
白丶魈白发布了新的文献求助10
3秒前
白丶魈白发布了新的文献求助10
3秒前
白丶魈白发布了新的文献求助10
3秒前
白丶魈白发布了新的文献求助10
3秒前
白丶魈白发布了新的文献求助10
3秒前
白丶魈白发布了新的文献求助10
4秒前
白丶魈白发布了新的文献求助10
4秒前
白丶魈白发布了新的文献求助10
4秒前
白丶魈白发布了新的文献求助10
4秒前
白丶魈白发布了新的文献求助10
4秒前
7秒前
开朗含海完成签到,获得积分10
13秒前
17秒前
在水一方的应助被mmyhn采纳,获得10
19秒前
科研通AI65的应助被hxjnx采纳,获得10
20秒前
sugar发布了新的文献求助10
20秒前
23秒前
虚心问旋完成签到,获得积分10
31秒前
33秒前
38秒前
39秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8195022
求助须知:如何正确求助?哪些是违规求助? 9580753
关于积分的说明 21872568
捐赠科研通 7794759
什么是DOI,文献DOI怎么找? 3437852
关于科研通互助平台的介绍 2561176
邀请新用户注册赠送积分活动 2484546